Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Athira Pharma

4 Analysts Have This to Say About Athira Pharma

Analysts have provided the following ratings for Athira Pharma (NASDAQ:ATHA) within the last quarter:

Benzinga · Jun 23, 2022

Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022

Upgrades

Benzinga · Jun 23, 2022

The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga · Jun 22, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Why Athira Pharma Stock Is Plunging

Athira Pharma Inc (NASDAQ: ATHA) shares are falling Wednesday after the company announced topline results from its exploratory ACT-AD Phase 2 study of fosgonimeton in patients with mild-to-moderate Alzheimer's disease.

Benzinga · Jun 22, 2022

Washington biotech firm and activist investor feud over control of Alzheimer's research

These are delicate times for Athira Pharma, a Bothell, Washington-based biotech firm in clinical trials for treatment for Alzheimer's and Parkinson's dementia.

Tribune News Service · May 12, 2022

Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2022

Upgrades

Benzinga · May 10, 2022

Earnings Preview: Athira Pharma

Athira Pharma (NASDAQ:ATHA) is set to give its latest quarterly earnings report on Thursday, 2022-03-24. Here's what investors need to know before the announcement. Analysts estimate that Athira Pharma will report an earnings per share (EPS) of $-0.54.

Benzinga · Mar 23, 2022

Read news from The Economist, FT, and more,
with one subscription

Organisations

Palantir Technologies

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

Washington D.C.

20,161 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.